Literature DB >> 26216751

Centhaquin improves survival in a swine model of hemorrhagic shock.

Panagiotis Papapanagiotou1, Theodoros Xanthos1, Anil Gulati2, Athanasios Chalkias3, Apostolos Papalois4, Zinais Kontouli5, Athanasios Alegakis6, Nicoletta Iacovidou7.   

Abstract

BACKGROUND: Hemorrhage is a frequent event in hospital and prehospital settings. The aim of the present study was to investigate whether centhaquin improves 24-h survival and reduces the total volume of required fluids in an established model of swine hemorrhagic shock.
MATERIAL AND METHODS: Twenty-five pigs were instrumented and subjected to hemorrhagic shock. The animals were randomly allocated in two experimental groups, the control (vehicle) (n = 10) and the centhaquin groups (0.015 mg/kg, n = 10); all animals received lactated Ringer solution in the resuscitation phase until their mean arterial pressure reached 90% of the baseline. A sham group (n = 5) was added a posteriori to mimic the hemodynamic profile of the centhaquin group.
RESULTS: A statistically significant difference was observed in the time required for the three groups to reach their target mean aortic pressure, 36.88 ± 3.26 min for the control group versus 9.40 ± 1.01 min for the sham group and 7.10 ± 0.97 min for the centhaquin group (P < 0.001). The total amount of fluids in the control and the sham groups was significantly higher when compared with that of the centhaquin-treated animals (P < 0.001). All 10 animals in the centhaquin group survived for 24 h, whereas only three animals survived in the control group and one animal in the sham group (P = 0.002).
CONCLUSIONS: Centhaquin 0.015 mg/kg administered in the fluid resuscitation phase resulted in lower volume of fluids and better survival compared with control and sham-operated animals.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Centhaquin; Fluids; Hemorrhagic shock; Resuscitation; Survival

Mesh:

Substances:

Year:  2015        PMID: 26216751     DOI: 10.1016/j.jss.2015.06.056

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  5 in total

Review 1.  Pathophysiology of Hemorrhage as It Relates to the Warfighter.

Authors:  Carmen Hinojosa-Laborde; Ian L Hudson; Evan Ross; Lusha Xiang; Kathy L Ryan
Journal:  Physiology (Bethesda)       Date:  2022-01-10

2.  Resuscitation with centhaquin and 6% hydroxyethyl starch 130/0.4 improves survival in a swine model of hemorrhagic shock: a randomized experimental study.

Authors:  Zinais Kontouli; Chryssoula Staikou; Nicoletta Iacovidou; Ioannis Mamais; Evaggelia Kouskouni; Apostolos Papalois; Panagiotis Papapanagiotou; Anil Gulati; Athanasios Chalkias; Theodoros Xanthos
Journal:  Eur J Trauma Emerg Surg       Date:  2018-07-13       Impact factor: 3.693

3.  Resuscitative Effect of Centhaquine (Lyfaquin®) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial.

Authors:  Anil Gulati; Dinesh Jain; Nilesh Radheshyam Agrawal; Prashant Rahate; Rajat Choudhuri; Soumen Das; Deba Prasad Dhibar; Madhav Prabhu; Sameer Haveri; Rohit Agarwal; Manish S Lavhale
Journal:  Adv Ther       Date:  2021-05-10       Impact factor: 3.845

4.  Baseline Values and Kinetics of IL-6, Procalcitonin, and TNF-α in Landrace-Large White Swine Anesthetized with Propofol-Based Total Intravenous Anesthesia.

Authors:  Athanasios Chalkias; Vaios Spyropoulos; Georgia Georgiou; Eleni Laou; Anastasios Koutsovasilis; Ioannis Pantazopoulos; Konstantina Kolonia; Spyros Vrakas; Apostolos Papalois; Styliani Demeridou; Konstantinos Gourgoulianis; Ismene Dontas; George Kaparos; Stavroula Baka; Theodoros Xanthos
Journal:  Biomed Res Int       Date:  2021-06-19       Impact factor: 3.411

5.  A Multicentric, Randomized, Controlled Phase III Study of Centhaquine (Lyfaquin®) as a Resuscitative Agent in Hypovolemic Shock Patients.

Authors:  Anil Gulati; Rajat Choudhuri; Ajay Gupta; Saurabh Singh; S K Noushad Ali; Gursaran Kaur Sidhu; Parvez David Haque; Prashant Rahate; Aditya R Bothra; Gyan P Singh; Sanjiv Maheshwari; Deepak Jeswani; Sameer Haveri; Apurva Agarwal; Nilesh Radheshyam Agrawal
Journal:  Drugs       Date:  2021-06-01       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.